EpilepsyGTx

EpilepsyGTx is a late preclinical-stage biotech developing cutting-edge gene therapies that will transform the management of focal refractory epilepsy (FRE).

Go to the UCLB homepage

We want you to have the best experience possible when using our website.

We use cookies to help us improve your user experience by collecting and reporting information on how you use the website via external analytical software. You can find out more by reading our Privacy Policy and Cookie Policy.